Compare · BNTX vs MRNA
BNTX vs MRNA
Side-by-side comparison of BioNTech SE (BNTX) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $63.11B, about 2.5x BNTX ($24.78B).
- Over the past year, BNTX is down 0.4% and MRNA is up 508.2% - MRNA leads by 508.6 points.
- MRNA has been more active in the news (20 items in the past 4 weeks vs 13 for BNTX).
- Both have 25 recent analyst ratings on file.
- Company
- BioNTech SE
- Moderna Inc.
- Price
- $95.92-2.84%
- $155.13-1.83%
- Market cap
- $24.78B
- $63.11B
- 1M return
- -15.20%
- -11.05%
- 1Y return
- -0.42%
- +508.16%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2018
- News (4w)
- 13
- 20
- Recent ratings
- 25
- 25
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest BNTX
- Chief Executive Officer Sahin Ugur sold $4,721,976 worth of Ordinary Shares (49,000 units at $96.37) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 553,209 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Executive Officer Sahin Ugur sold $8,439,336 worth of Ordinary Shares (86,000 units at $98.13) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 602,209 units (SEC Form 4)
- SEC Form 6-K filed by BioNTech SE
- BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
- Chief Executive Officer Sahin Ugur sold $1,974,287 worth of Ordinary Shares (20,500 units at $96.31) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 688,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $7,190,663 worth of Ordinary Shares (73,000 units at $98.50) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 708,709 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $7,889,055 worth of Ordinary Shares (76,500 units at $103.12) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 781,709 units (SEC Form 4)
- BioNTech downgraded by BMO Capital Markets with a new price target
- SEC Form 6-K filed by BioNTech SE
Latest MRNA
- President Hoge Stephen exercised 152,905 shares at a strike of $12.21 and sold $11,691,420 worth of shares (80,575 units at $145.10) as part of a pre-agreed trading plan, increasing direct ownership by 5% to 1,562,029 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Mock James M exercised 19,836 shares at a strike of $30.96 and sold $4,685,094 worth of shares (34,836 units at $134.49) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 59,375 units (SEC Form 4)
- Chief Financial Officer Mock James M converted options into 11,797 shares and covered exercise/tax liability with 5,704 shares, increasing direct ownership by 9% to 74,375 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 5,704 shares and converted options into 11,797 shares, increasing direct ownership by 8% to 81,340 units (SEC Form 4) (withholding obligation)
- Chief Legal Officer Klinger Shannon Thyme sold $485,766 worth of shares (3,471 units at $139.95) as part of a pre-agreed trading plan, covered exercise/tax liability with 1,048 shares and exercised 5,637 shares at a strike of $19.06, increasing direct ownership by 2% to 75,247 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M covered exercise/tax liability with 1,197 shares and converted options into 2,475 shares, increasing direct ownership by 2% to 68,282 units (SEC Form 4) (for withholding tax)
- President Hoge Stephen converted options into 9,283 shares and covered exercise/tax liability with 4,489 shares, increasing direct ownership by 0.32% to 1,489,699 units (SEC Form 4) (tax liability)
- Moderna downgraded by Rothschild & Co Redburn with a new price target
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement